Advertisement

Topics

BioSense Acquires China Rights to Rexahn's Pancreatic Cancer Drug in $226 Million Deal

07:45 EDT 17 Apr 2019 | ChinaBio Today

BioSense, a New Jersey-Suzhou biopharma, acquired Greater China rights to a Rexahn treatment for pancreatic cancer in a deal potentially worth $226 million. BioSense, which will fund all development and commercialization costs for RX-3117 in Greater China, also agreed to start Phase II tests in up to three additional indications for RX-3117 not previously studied by Rexahn. RX-3117 is a novel oral small-molecule nucleoside compound that inhibits both DNA and RNA synthesis, which induces apoptosis. More details....

Stock Symbol: (NYSE American: RNN)

Share this with colleagues:

Original Article: BioSense Acquires China Rights to Rexahn's Pancreatic Cancer Drug in $226 Million Deal

NEXT ARTICLE

More From BioPortfolio on "BioSense Acquires China Rights to Rexahn's Pancreatic Cancer Drug in $226 Million Deal"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pancreatitis
Pancreatitis Acute pancreatitis is inflammation of the pancreas caused by the release of activated pancreatic enzymes. Common triggers are biliary tract disease and chronic heavy alcohol intake.  Diagnosis is based on clinical presentation...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...